Article Critique Sample: Critical Appraisal of an RCT on Wound-Care Dressings

Model Answer

Overview of the Article

This critique appraises Bramwell, Achebe and Sutcliffe (2021), a single-centre randomised controlled trial titled ‘Silver-Impregnated versus Standard Hydrocolloid Dressings for Venous Leg Ulcers’, published in the Journal of Wound Care and Tissue Viability. The trial compared time to 50% reduction in wound surface area, infection rate, and patient-reported pain between two dressing types in adults with confirmed venous leg ulcers attending a community tissue-viability service. Ninety participants were randomised 1:1 to silver-impregnated or standard hydrocolloid dressings, with weekly assessment over twelve weeks by an assessor blinded to allocation. The authors reported a statistically significant reduction in time to 50% wound area reduction in the silver-dressing group, alongside a lower infection rate, and concluded that silver-impregnated dressings should be considered first-line for venous leg ulcers of this severity. This critique uses the CASP (2022) Randomised Controlled Trial checklist as a structured appraisal framework.

Aims and Rationale

The trial’s aim — to compare healing outcomes between silver-impregnated and standard hydrocolloid dressings in venous leg ulceration — is precisely stated and clinically relevant, addressing a genuine gap given inconsistent findings in earlier, smaller studies. The rationale is well grounded: the authors cite the substantial NHS cost burden of chronic wound care and the variation in dressing selection across community services, situating the study within a recognised evidence gap identified in prior NICE (2019) guidance on chronic wound management. The population, intervention, comparator and outcome (PICO) elements are all clearly specified in the introduction, which strengthens the transparency of the research question and allows the reader to judge the trial’s applicability to their own clinical setting. One area of concern is that the authors do not explicitly justify why silver-impregnated dressings, rather than other advanced wound-care technologies such as foam or alginate dressings, were selected as the comparator’s alternative; a brief discussion of why this particular head-to-head comparison was prioritised over others would have strengthened the rationale. The introduction also situates the study within relevant NICE quality standards for wound care, strengthening the argument that the trial addresses a genuine and current practice-relevant question for community nursing teams rather than a purely academic one. Overall, the aims are appropriately scoped for a single-centre trial and align well with a genuine clinical decision faced by tissue-viability nurses.

Methodology

This was a single-centre, assessor-blinded randomised controlled trial, an appropriate design for establishing comparative effectiveness between two active interventions. Randomisation was computer-generated with allocation concealed via sequentially numbered opaque envelopes, a method that reduces selection bias in line with CONSORT (2010) reporting standards. A priori sample size calculation based on an anticipated 20-percentage-point difference in healing rate at 80% power and a 5% significance level indicated a need for 84 participants; the trial recruited 90, which is adequate. Inclusion criteria (confirmed venous aetiology via Doppler, ulcer duration under twelve months, ankle-brachial pressure index within a defined range) and exclusion criteria (diabetic ulceration, arterial disease, current antibiotic therapy) were clearly reported and clinically sensible, reducing the risk of confounding by wound aetiology. Outcome assessment — time to 50% wound area reduction (measured via standardised digital planimetry), infection rate (defined using validated clinical criteria), and pain (10-point visual analogue scale) — used a mix of objective and patient-reported measures, and the assessor recording wound area was blinded to group allocation, which guards against detection bias. Patients themselves could not be blinded to dressing type, an unavoidable limitation of this intervention type. Ethical approval was obtained from the NHS Health Research Authority (2021), with informed consent and adherence to Good Clinical Practice and the Nursing and Midwifery Council’s (2018) Code; this is appropriately documented. Applying the CASP (2022) RCT checklist systematically, the randomisation and blinding domains score strongly, while the domain addressing completeness of follow-up is weaker, since the handling of the eight withdrawals is not transparently reported in the results section, a gap that a structured appraisal tool is well suited to surfacing. A minor weakness is that adherence to the twelve-week protocol in community settings is not reported, which could introduce unmeasured variation in the delivered intervention.

Results and Analysis

Table 1 summarises the trial’s key outcomes by group.

Silver-impregnated dressings were associated with a significantly shorter median time to 50% wound area reduction (5.2 weeks versus 7.8 weeks, p = .01) and a lower infection rate (6.7% versus 17.8%, p = .04) than standard hydrocolloid dressings, with no statistically significant difference in reported pain scores. These are clinically meaningful differences reported with appropriate p-values, and the chosen non-parametric test suits the likely non-normal distribution of healing times. The authors appropriately avoid extrapolating beyond the measured twelve-week window, which is a strength given the wound was not followed to full closure in all participants. Baseline characteristics are presented in a separate table (not reproduced here) and appear broadly balanced across groups for age, sex and ulcer duration, which supports the credibility of the randomisation process despite the slight imbalance noted in initial wound size. However, the manuscript does not report an intention-to-treat analysis separately from a per-protocol analysis, and with eight participants lost to follow-up (four per group), it is unclear whether missing data were handled in a way that avoids overestimating treatment effect. No adjustment is reported for baseline wound size, which differed slightly (though not significantly) between groups at randomisation and could plausibly have influenced healing time independently of dressing type. The infection-rate result, while statistically significant, is based on a modest absolute number of events (three versus eight), which appraisal tools such as CASP flag as a point requiring cautious interpretation given the risk of a fragile p-value driven by few events.

Discussion and Conclusions

The authors interpret their findings as clear support for silver-impregnated dressings as a first-line option in venous leg ulcer management, linking the reduced infection rate to silver’s established antimicrobial properties (Craig and Ferrante, 2020) and the faster healing time to reduced bioburden facilitating epithelialisation. This interpretation is broadly consistent with existing tissue-viability literature and is presented with appropriate caveats regarding cost, since silver dressings are considerably more expensive per unit than standard hydrocolloid. Where the discussion slightly overreaches is in its concluding recommendation that silver-impregnated dressings ‘should replace’ standard hydrocolloid as first-line treatment; this single-centre trial, while well conducted, has not been replicated, and NICE evidence hierarchies generally require corroboration from multiple trials or a systematic review before informing a blanket change in first-line practice. The authors do acknowledge the need for further multi-centre trials in a single sentence, but this caveat is not reflected proportionately in the abstract, which a busy clinician reading only the summary might reasonably interpret as more definitive than the body of evidence supports. A more cautious conclusion — for example, recommending silver-impregnated dressings as an option to be considered case-by-case pending further trials — would have matched the strength of a single, unreplicated trial more closely than the stronger wording the authors ultimately chose. The cost-effectiveness argument, while plausible, is asserted rather than formally modelled (cf. Okonkwo and Lindqvist, 2019); a full cost-utility analysis was outside this trial’s scope but its absence limits the strength of any resource-allocation conclusion that could be drawn directly from this paper alone.

Strengths and Limitations

This trial has clear methodological strengths: computer-generated randomisation with concealed allocation, assessor blinding for the primary outcome, an adequately powered sample, clearly defined inclusion and exclusion criteria, and use of a combination of objective and patient-reported outcome measures. Reporting broadly follows CONSORT conventions, which supports transparency and aids replication by other tissue-viability teams. It is also worth noting that funding source and any conflicts of interest are disclosed transparently in accordance with journal policy, which supports confidence that the reported findings were not shaped by commercial pressure from the dressing manufacturer. Set against these strengths, several limitations temper the conclusions, consistent with recognised methodological concerns about blinding in wound-care trials (Renfrew, 2022). The single-centre design limits generalisability to community services with different patient demographics, staffing skill mix, or dressing-change protocols. Participants and treating nurses could not be blinded to dressing type, given the visibly different appearance of the two products, which introduces a risk of performance bias, particularly for the patient-reported pain outcome. The eight participants lost to follow-up, and the absence of a clearly reported intention-to-treat analysis, leave some uncertainty about whether the results would hold under stricter analytic handling of missing data. The infection-rate finding, while statistically significant, rests on a modest absolute number of events, making it more vulnerable to chance variation than the headline p-value alone suggests. Finally, the twelve-week follow-up captures healing progress but not full wound closure or ulcer recurrence, an outcome of considerable importance to patients and to service planning for chronic wound care.

Overall Judgement

Taken as a whole, this is a well-designed and clinically relevant single-centre RCT that adds useful evidence to the tissue-viability literature on dressing selection for venous leg ulcers. Its strengths in randomisation, blinding and outcome measurement place it above much comparable wound-care research, and its findings offer a reasonable basis for tissue-viability nurses to consider silver-impregnated dressings for patients with slow-healing or high infection-risk venous ulcers. However, the single-centre setting, incomplete handling of missing data, and a headline infection-rate result built on a small number of events mean the trial’s conclusions should inform practice cautiously rather than prompt an immediate blanket change in first-line dressing policy. In line with NICE’s evidence-hierarchy expectations, this trial is best regarded as a valuable single contribution that warrants replication in a multi-centre trial with longer follow-up and a formal cost-utility analysis before its recommendations are adopted service-wide. Clinicians should also weigh the cost differential against the modest absolute healing-time benefit when making formulary decisions locally.

References

Bramwell, T., Achebe, N. and Sutcliffe, J. (2021) ‘Silver-impregnated versus standard hydrocolloid dressings for venous leg ulcers: a randomised controlled trial’, Journal of Wound Care and Tissue Viability, 30(9), pp. 604–615.

CONSORT Group (2010) CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. Ottawa: CONSORT.

Craig, D. and Ferrante, L. (2020) ‘Antimicrobial dressings in chronic wound management: a review of the evidence’, Wound Management Research, 11(2), pp. 88–101.

Critical Appraisal Skills Programme (2022) CASP Randomised Controlled Trial Checklist. Oxford: CASP.

Health Research Authority (2021) UK Policy Framework for Health and Social Care Research. London: HRA.

National Institute for Health and Care Excellence (2019) Chronic Wounds: Advanced Wound Dressings and Antimicrobial Dressings. London: NICE.

Nursing and Midwifery Council (2018) The Code: Professional Standards of Practice and Behaviour for Nurses, Midwives and Nursing Associates. London: NMC.

Okonkwo, P. and Lindqvist, H. (2019) ‘Cost-effectiveness of advanced wound dressings in community nursing: a systematic review’, Journal of Community Nursing Economics, 7(3), pp. 145–160.

Renfrew, K. (2022) ‘Blinding and bias in wound-care trials: methodological considerations’, Nursing Research Methods Bulletin, 4(1), pp. 22–34.